Table 1.
Subject characteristics in 19 episodes of CSF/plasma discordance >0.5log10 versus 21 without discordance.
| Discordant (n = 19) | Non-discordant (n=21) | p value | |
|---|---|---|---|
| Age, median years (IQR) | 47 (44, 57) | 47 (41, 53) | 0.577 |
| Gender male, n (%) | 15 (78.9) | 15 (71.4) | 1.00 |
| Ethnicity, n (%) | 0.408 | ||
| White MSM | 8 (42.1) | 12 (57.1) | |
| Black heterosexual | 6 (31.6) | 3 (14.3) | |
| Other | 5 (26.3) | 6 (28.6) | |
| CD4 | |||
| Current, median cells/μl (IQR) | 380 (319, 490) | 464 (359, 741) | 0.189 |
| Nadir, median cells/μl (IQR) | 31 (27, 79) | 112 (34, 283) | 0.102 |
| Time since HIV diagnosis, median years (IQR) | 13.0 (9.3, 18.0) | 8.0 (4.5, 16.5) | 0.087 |
| ART at sampling, n (%) | 0.306 | ||
| PI/r | 17 (89.5) | 13 (61.9) | |
| NNRTI | 2 (10.5) | 7 (33.3) | |
| NRTI | 17 (89.5) | 18 (85.7) | |
| RAL | 5 (26.3) | 2 (9.5) | |
| MVC | 2 (10.5) | 3 (14.3) | |
| CPE score (2010), median (IQR) | 7 (7, 8) | 7 (6, 9) | 0.903 |
| Self reported adherence <95%, n (%) | 2 (10.5) | 2 (9.5) | 1.00 |
| Indication for LP, n (%) | 0.139 | ||
| Research LP (LLV group) | 8 (42.1) | 8 (38.1) | |
| Cognitive symptoms | 5 (26.3) | 2 (9.5) | |
| Headache | 0 (0.0) | 3 (14.3) | |
| Suspected CNS infection | 1 (5.3) | 2 (9.5) | |
| Follow up previous CNS infectiona | 3 (15.8) | 0 (0.0) | |
| Abnormal neurological exam | 1 (5.3) | 4 (19.0) | |
| Other | 1 (5.3) | 2 (9.5) | |
a
CNS toxoplasmosis, EBV encephalitis and VZV encephalitis. IQR, interquartile range; MSM, men who have sex with men; IVDU, intravenous drug user; LP, lumbar puncture; CNS, central nervous system; CSF, cerebrospinal fluid; CPE, CNS penetration effectiveness score (2010); ART, antiretroviral therapy; PI/r, ritonavir boosted protease inhibitor; NNRTI, non nucleoside reverse transcriptase inhibitor; RAL, raltegravir; MVC, maraviroc; RNA, ribonucleic acid.